330350.KQ Withuspharmaceutical Co.Ltd
- Market cap
- KRW 84.1B
- P/E
- 10.5x
- P/B
- 0.81x
- ROE
- 11.4%
- Dividend yield
- -
- Fundamental score
- 2.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 330350.KQ undervalued?
Graham number330350.KQ trades 38.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Withuspharmaceutical Co.Ltd fundamental analysis
14 of 22 checks passedROE 1/2
Moderate return on equity (11.4%), between 10% and 20%.
ROA 1/1
Return on assets (8.2%) is above the industry median (1.4%).
Profit Consistency 2/2
Profitable for 9 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (3.8%) is not above the 5-year average (21.6% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (3.8%) is above the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 18.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 1/1
PE (10.5x) is below the market median (11.3x).
PE vs Industry 1/1
PE (10.5x) is below the industry median (11.4x).
PBV 1/1
Price to book (0.8x) is below the industry median (0.9x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 8.5, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.49, growth is cheap.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Withuspharmaceutical Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Withuspharmaceutical Co.Ltd
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products. The company wa…
Full company profileWithuspharmaceutical Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Withuspharmaceutical Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 50.9B | 51.7B | 52.4B | 26.2B | 57.4B | 64.7B | 80.1B | 103B | 106B | 115B |
| Gross Profit | 30.8B | 32.0B | 33.0B | 15.1B | 33.5B | 38.3B | 48.6B | 65.6B | 68.8B | 73.7B |
| Operating Income | 11.3B | 10.9B | 9.74B | 1.36B | 4.89B | 4.88B | 7.91B | 5.46B | 5.66B | 2.64B |
| EBITDA | - | - | - | - | - | 6.50B | 12.6B | 9.73B | 9.31B | 8.18B |
| Net Income | 8.49B | 8.66B | 8.04B | 1.87B | 4.26B | 2.48B | 7.96B | 4.78B | 4.97B | 11.9B |
| EPS | 730 | 745 | 610 | 142 | 323 | 188 | 603 | 362 | 376 | 900 |
| Balance Sheet | ||||||||||
| Total Assets | 69.0B | 76.3B | 107B | 106B | 119B | 119B | 131B | 135B | 137B | 144B |
| Total Liabilities | 24.9B | 23.9B | 30.3B | 29.3B | 38.1B | 36.4B | 40.5B | 41.6B | 38.6B | 40.1B |
| Shareholders' Equity | 44.1B | 52.4B | 76.8B | 76.9B | 80.9B | 83.0B | 90.3B | 93.1B | 98.0B | 104B |
| Cash & Short-term Investments | 22.0B | 28.6B | 44.7B | 39.4B | 42.5B | 26.6B | 11.2B | 18.9B | 17.4B | 18.9B |
| Total Debt | 13.0B | 10.2B | 13.4B | 15.0B | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 6.65B | 6.77B | 7.93B | 810M | 8.02B | 5.38B | -1.24B | 9.63B | 6.78B | 12.9B |
| Capital Expenditure | 2.40B | 1.96B | 4.67B | 5.26B | 6.67B | 15.3B | 12.0B | 6.56B | 3.11B | 10.4B |
| Free Cash Flow | - | - | 2.79B | -3.21B | -2.27B | -12.4B | -13.2B | 3.07B | 3.67B | 2.42B |
| Ratios | ||||||||||
| ROE | 19.3% | 16.5% | 10.5% | 2.4% | 5.3% | 3.0% | 8.8% | 5.1% | 5.1% | 11.4% |
| ROA | 12.3% | 11.4% | 7.5% | 1.8% | 3.6% | 2.1% | 6.1% | 3.6% | 3.6% | 8.2% |
| Net Profit Margin | 16.7% | 16.7% | 15.3% | 7.1% | 7.4% | 3.8% | 9.9% | 4.7% | 4.7% | 10.4% |
| Debt to Equity | 0.29x | 0.20x | 0.17x | 0.20x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Withuspharmaceutical Co.Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 27, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | KRW 1.32B | 100 | 27.6% |
| 2023 | - | - | - |
| 2022 | KRW 633M | 48 | 25.5% |
| 2021 | KRW 422M | 32 | 9.9% |
| 2020 | KRW 3.60B | 273 | 193.0% |
| 2019 | KRW 3.60B | 273 | 44.8% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jun 11, 2021.
Who owns Withuspharmaceutical Co.Ltd
- Insiders 53.53%
- Institutions 0.00%
- Public & others 46.47%
- Shares outstanding 13.2M
- Free float 6.13M
Withuspharmaceutical Co.Ltd company profile
- Company name
- Withuspharmaceutical Co.Ltd
- Ticker
- 330350.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Fiscal year end
- December
- Address
- Withus Building, Seoul, South Korea
- Phone
- 82 2 3486 7474
- Website
- withuspharm.com
About Withuspharmaceutical Co.Ltd
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products. The company was previously known as Withers Medipharm Co., Ltd. and changed its name to WITHUS PHARMACEUTICAL Co.,LTD. in October 2007. WITHUS PHARMACEUTICAL Co.,LTD. was founded in 2004 and is headquartered in Seoul, South Korea.
Withuspharmaceutical Co.Ltd management
2- Mr. Dae-young SungCEO & Executive Director · born 1959
- GwangYoung KwonVP & Executive Director · born 1961